{
    "clinical_study": {
        "@rank": "137787", 
        "arm_group": {
            "arm_group_label": "Mircera Arm", 
            "arm_group_type": "Experimental", 
            "description": "Once Monthly Mircera"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of study is to evaluate the no of patients which maintain the Hb level\n      between 9.0 ~ 12.0 g/dl during the evaluation period"
        }, 
        "brief_title": "Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "PD", 
        "detailed_description": {
            "textblock": "The secondary objective of study is\n\n        -  No of patients with mean Hb level of +/-1.0g/dl difference from the baseline Hb\n\n        -  Incidence of RBC transfusion during the titration and evaluation periods\n\n        -  Mean Hb during the total study period\n\n        -  Intrapatient Hb variability (mean within-patient standard deviation for Hb)\n\n        -  Frequency of Micera dose level\n\n        -  safety"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  1.\u226518 yr of age\n\n          -  2.peritoneal dialysis for \u226512wk before screening and during baseline period\n\n          -  3.weekly Kt/V \u22651.8 for PD patients\n\n          -  4.Baseline Hb concentration between 9.0 and 12.0g/dl(mean of the monthly Hb values\n             determined in month -2 and -1)\n\n          -  5.stable baseline Hb concentration(defined as an absolute difference \u22642g/dl between\n             the Hb values determined in month -2 and -1)\n\n          -  6.continuous subcutaneous maintenance epoetin or darbepoetin therapy for at least 2\n             months before screening and during baseline period\n\n          -  7.adequate iron status defined as serum ferritin \u2265 100ng/ml or transferrin\n             saturation\u226520%(mean of two values deteremined in month -2 and -1)\n\n        Exclusion criteria:\n\n          -  1.Overt gastrointestinal bleeding or any other bleeding episode necessitating\n             transfusion wihin 2 months before screening during baseline pereiod\n\n          -  2.RBC transfusions within 2 months before screening or during baseline period\n\n          -  3.nonrenal causes of anemia(e.g folic acid or vitamin B12 deficiency,hemolysis)\n\n          -  4.acute infection or chronic, uncontrolled or symptomatic inflammatory disease(e.g\n             rhematoid arthritis,systemic lupus erythematosus)\n\n          -  5.C-reactive protein>30mg/dl\n\n          -  6.poorly controlled hypertension necessitating interruption of epotien or darbepoetin\n             in the 6 months before screening\n\n          -  7.platelets > 500X109/L\n\n          -  8.pure red cell aplasia\n\n          -  9.chronic congestive heart failure(New Yorj Heart Association class IV)\n\n          -  10.Myocardial infarction,severe or unstable coronary artery disease,stroke,severe\n             liver disease within the 3months before screening or during baseline\n\n          -  11.Life expectancy < 12months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "101", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01807481", 
            "org_study_id": "SMC 2011-10-131"
        }, 
        "intervention": {
            "arm_group_label": "Mircera Arm", 
            "description": "Once Monthly Mircera", 
            "intervention_name": "Mircera", 
            "intervention_type": "Drug", 
            "other_name": "Mircera"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Mircera", 
            "PD", 
            "Maitenance"
        ], 
        "lastchanged_date": "June 11, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Dae Joong Kim"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Dae Joong Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Dae Joon g Kim"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Dae Joong Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Prospective,Single-arm,Multicenter Study to Evaluate the Efficacy and Safety of Mircera in Peritoneal Patients Who Already Had Been Treated With ESA", 
        "overall_contact": {
            "email": "daejoong.smc.kim@samsung.com", 
            "last_name": "Dae Joong Kim", 
            "phone": "82234103441"
        }, 
        "overall_contact_backup": {
            "last_name": "Dae Joong Kim"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Dae Joong Kim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary objective of this study is to evaluate the no of patients which maintain the Hb-level between  10.0~13.0 g/dL during the evaluation period", 
            "measure": "Number of patients with hemoglobin 10~12 g/dl", 
            "safety_issue": "Yes", 
            "time_frame": "Visit 0 ~ visit 10 (10 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01807481"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Kim Dae Joong", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Incidence of RBC transfusion during the titration and evaluation periods Mean Hb during the total study period Intrapatient Hb variability (mean within patient standard deviations for Hb) Comparison between baseline and evaluation period mean Hb level Frequency of dose adjustments Safety", 
            "measure": "Hemoglobin stability, Dose adjustment", 
            "safety_issue": "Yes", 
            "time_frame": "Visit0~Visit 10 (10 Months)"
        }, 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}